肠溶阿司匹林致冠心病患者上消化道出血调查分析

目的探讨肠溶阿司匹林导致冠心病患者出现上消化道出血的具体原因。 方法回顾性分析2016年1月至2017年12月青岛市城阳区人民医院收治的的68例冠心病患者的临床资料，分析肠溶阿司匹林导致冠心病患者出现上消化道出血的具体原因。 结果68例冠心病患者中38例发生上消化道出血，上消化道出现发生率为55.88%。出血患者用药剂量为300 mg/d、用药时间>3个月、存在消化道病史、未使用胃黏膜保护剂比例高于未出血患者，差异有统计学意义(均P<0.05)。 结论冠心病患者肠溶阿司匹林致上消化道出血的原因较多，包括用药剂量大，用药时间长，存在消化道病史，未服用胃黏膜保护剂等。

Investigation and analysis of upper gastrointestinal bleeding caused by enteric-coated aspirin in patients with coronary heart disease

ObjectiveTo explore the reasons of upper gastrointestinal bleeding caused by enteric-coated aspirin in patients with coronary heart disease. MethodsThe clinical data of 68 patients with coronary heart disease admitted to Chengyang District People's Hospital of Qingdao City from January 2016 to December 2017 were retrospectively analyzed. The specific reasons of upper gastrointestinal bleeding caused by enteric-coated aspirin were analyzed. ResultsIn 68 patients with coronary heart disease, 38 patients had upper gastrointestinal bleeding, and the incidence of upper gastrointestinal bleeding was 55.88%. The dosage of 300 mg/d, duration of medication > 3 months, history of digestive tract disease and the proportion of patients who did not receive gastric mucosa protective agents were higher in patients with upper gastrointestinal bleeding than those without upper gastrointestinal bleeding, and the differences were statistically significant (all P<0.05). ConclusionThere are many reasons of upper gastrointestinal bleeding caused by enteric-coated aspirin in patients with coronary heart disease, including high dosage, long duration of medication, history of gastrointestinal diseases, and not taking gastric mucosa protective agents.